Chiarugi A - Search Results

1

Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Haskó G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sümegi B, Swanson RA, Szabo C. Berger NA, et al. Among authors: chiarugi a. Br J Pharmacol. 2018 Jan;175(2):192-222. doi: 10.1111/bph.13748. Epub 2017 Mar 26. Br J Pharmacol. 2018. PMID: 28213892 Free PMC article. Review.

2

Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase.

Chiarugi A, Carpenedo R, Molina MT, Mattoli L, Pellicciari R, Moroni F. Chiarugi A, et al. J Neurochem. 1995 Sep;65(3):1176-83. doi: 10.1046/j.1471-4159.1995.65031176.x. J Neurochem. 1995. PMID: 7643095

3

Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities.

Carpenedo R, Chiarugi A, Russi P, Lombardi G, Carlà V, Pellicciari R, Mattoli L, Moroni F. Carpenedo R, et al. Among authors: chiarugi a. Neuroscience. 1994 Jul;61(2):237-43. doi: 10.1016/0306-4522(94)90227-5. Neuroscience. 1994. PMID: 7969905

4

Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase.

Chiarugi A, Carpenedo R, Moroni F. Chiarugi A, et al. J Neurochem. 1996 Aug;67(2):692-8. doi: 10.1046/j.1471-4159.1996.67020692.x. J Neurochem. 1996. PMID: 8764597

5

Kynurenine hydroxylase and kynureninase inhibitors as tools to study the role of kynurenine metabolites in the central nervous system.

Moroni F, Carpenedo R, Chiarugi A. Moroni F, et al. Among authors: chiarugi a. Adv Exp Med Biol. 1996;398:203-10. doi: 10.1007/978-1-4613-0381-7_33. Adv Exp Med Biol. 1996. PMID: 8906267 Review. No abstract available.

6

Identification and measurement of oxindole (2-indolinone) in the mammalian brain and other rat organs.

Carpenedo R, Carlà V, Moneti G, Chiarugi A, Moroni F. Carpenedo R, et al. Among authors: chiarugi a. Anal Biochem. 1997 Jan 1;244(1):74-9. doi: 10.1006/abio.1996.9854. Anal Biochem. 1997. PMID: 9025911

7

Studies on the pharmacological properties of oxindole (2-hydroxyindole) and 5-hydroxyindole: are they involved in hepatic encephalopathy?

Moroni F, Carpenedo R, Mannaioni G, Galli A, Chiarugi A, Carlà V, Moneti G. Moroni F, et al. Among authors: chiarugi a. Adv Exp Med Biol. 1997;420:57-73. doi: 10.1007/978-1-4615-5945-0_4. Adv Exp Med Biol. 1997. PMID: 9286426 Review. No abstract available.

8

Effects of mitochondria and o-methoxybenzoylalanine on 3-hydroxyanthranilic acid dioxygenase activity and quinolinic acid synthesis.

Chiarugi A, Moroni F. Chiarugi A, et al. J Neurochem. 1999 Mar;72(3):1125-32. doi: 10.1046/j.1471-4159.1999.0721125.x. J Neurochem. 1999. PMID: 10037484 Free article.

9

The kynurenine metabolic pathway in the eye: studies on 3-hydroxykynurenine, a putative cataractogenic compound.

Chiarugi A, Rapizzi E, Moroni F, Moroni F. Chiarugi A, et al. FEBS Lett. 1999 Jun 18;453(1-2):197-200. doi: 10.1016/s0014-5793(99)00724-3. FEBS Lett. 1999. PMID: 10403402 Free article.

10

Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesul fonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase.

Chiarugi A, Moroni F. Chiarugi A, et al. Neuropharmacology. 1999 Aug;38(8):1225-33. doi: 10.1016/s0028-3908(99)00048-9. Neuropharmacology. 1999. PMID: 10462134

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193 results

Search Page